Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study

REVELATION BIOSCIENCES, INC.

2026-Q1 EPS reported -$2.71

Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.
Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.
FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.
Received $6.7M net proceeds from January 2026 warrant inducement.
Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2026 results: net income $3.0 million, or $2.71 basic and diluted net loss per share.

Period: three months ended March 31, 2026
Net income: $3.0 million, or $2.71 basic and diluted net loss per share
Result: reported results

Exact text from the filing

31, 2026 was $3.2 million compared to net cash used for operating activities of $2.8 million for the same period in 2025. Net loss for the three months ended March 31, 2026 was $3.0 million, or $2.71 basic and diluted net loss per share compared to net loss of $2.1 million, or $25.34 basic and diluted net loss per share for the three months ended March 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-212064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.